)
)
Respiratorius Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Respiratorius
Access all reports
Respiratorius AB is a Swedish biotechnology company focused on developing drug candidates for the treatment of various diseases, primarily cancer, COPD (Chronic Obstructive Pulmonary Disease), and asthma. Its lead project, VAL001, is aimed at enhancing the treatment of Diffuse Large B-Cell Lymphoma (DLBCL), the most common type of aggressive lymphoma. Additionally, the company is developing substances like the RESP series, which have bronchodilating effects for respiratory conditions such as COPD and asthma. Respiratorius is also working on a cardiovascular biomarker to aid in PET imaging diagnostics. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Adobe: Equipping the Architects of Digital Expression
The story of how Adobe grew from a small garage upstart to one of the largest and most dominant software companies in the world.
21 Mar 2025
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
Ticker symbol
RESP
Country
🇸🇪 Sweden